The subject of the present invention is a weakly corrosive and weakly coloured sulfonic acid, with an APHA colour index of less than 20, comprising chlorides and nitrites in a chloride/sulfonic acid molar ratio of between 1 ppm and 200 ppm, and a nitrite/sulfonic acid molar ratio of between 200 ppm and 6000 ppm, limits inclusive.

The subject of the present invention is a weakly corrosive and weakly coloured sulfonic acid, with an APHA colour index of less than 20, comprising chlorides and nitrites in a chloride/sulfonic acid molar ratio of between 1 ppm and 200 ppm, and a nitrite/sulfonic acid molar ratio of between 200 ppm and 6000 ppm, limits inclusive.

The present invention provides a high-purity arylsulfonic acid amine salt vinyl monomer which is an extremely industrially useful arylsulfonic acid monomer with excellent storage stability and amphiphilic solubility in both water and organic solvents, a simple and practical method for producing the same, a polyarylsulfonic acid amine salt which is a polymer thereof, and a method for producing the same. In the arylsulfonic acid amine salt vinyl monomer, a tertiary amine having 2 or 3 different substituents that each have 1 to 7 carbon atoms and also containing at least one or more of tertiary carbon or quaternary carbon or cyclic skeleton in the structure is applied to an amine moiety thereof, and in addition, a polyarylsulfonic acid amine salt having high purity in terms of sulfonation rate and polymerization conversion rate and a polymer thereof are used.

Disclosed are a fused tricyclic -amino acid derivative and a medical use thereof, in particular, the present invention relates to a fused cyclic -amino acid derivative as shown in general formula (I), or a stereoisomer, solvate, metabolite, prodrug, pharmaceutically acceptable salt or eutectic thereof, a pharmaceutical composition containing same, and the use of a compound or the composition in the field of analgesia, wherein the definitions of each substituent in general formula (I) are the same as the definitions in the description. ##STR00001##

Disclosed are a fused tricyclic -amino acid derivative and a medical use thereof, in particular, the present invention relates to a fused cyclic -amino acid derivative as shown in general formula (I), or a stereoisomer, solvate, metabolite, prodrug, pharmaceutically acceptable salt or eutectic thereof, a pharmaceutical composition containing same, and the use of a compound or the composition in the field of analgesia, wherein the definitions of each substituent in general formula (I) are the same as the definitions in the description. ##STR00001##

The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.

The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.

The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.

The invention relates to besylate salts of the compound of formula (I):

##STR00001##

Methods of preparing the salts, and their use as medicaments, in particular for sedative or hypnotic, anxiolytic, muscle relaxant, or anticonvulsant purposes is also described.

The invention relates to besylate salts of the compound of formula (I):

##STR00001##

Methods of preparing the salts, and their use as medicaments, in particular for sedative or hypnotic, anxiolytic, muscle relaxant, or anticonvulsant purposes is also described.